MX2020002977A - Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos. - Google Patents

Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.

Info

Publication number
MX2020002977A
MX2020002977A MX2020002977A MX2020002977A MX2020002977A MX 2020002977 A MX2020002977 A MX 2020002977A MX 2020002977 A MX2020002977 A MX 2020002977A MX 2020002977 A MX2020002977 A MX 2020002977A MX 2020002977 A MX2020002977 A MX 2020002977A
Authority
MX
Mexico
Prior art keywords
glp1
peptide
modified
glucagon
receptor agonists
Prior art date
Application number
MX2020002977A
Other languages
English (en)
Inventor
Andrew J Murphy
Samuel Davis
Haruka Okamoto
Jesper Gromada
Yang Wei
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020002977A publication Critical patent/MX2020002977A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invención provee polipéptidos de péptido 1 similar al glucagón tipo 1 (GLP1) modificado, proteínas de fusión que comprenden polipéptidos de GLP1 modificado y métodos de uso de los mismos. En diversas modalidades de la invención, las proteínas de fusión son agonistas de receptor de GLP1 que comprenden un GLP1 modificado fusionado a un dominio estabilizador. En algunas modalidades, las proteínas de fusión que comprenden GLP1 modificado son útiles para tratar o mejorar un síntoma o indicación de un trastorno tal como obesidad y diabetes.
MX2020002977A 2017-09-22 2018-09-21 Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos. MX2020002977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020002977A true MX2020002977A (es) 2020-11-06

Family

ID=63799082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002977A MX2020002977A (es) 2017-09-22 2018-09-21 Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.

Country Status (14)

Country Link
US (4) US11045522B2 (es)
EP (1) EP3684793A1 (es)
JP (3) JP7239566B2 (es)
KR (1) KR102696518B1 (es)
CN (2) CN111108117B (es)
AU (2) AU2018338178B2 (es)
CA (1) CA3073964A1 (es)
EA (1) EA202090649A1 (es)
IL (2) IL273253B2 (es)
MX (1) MX2020002977A (es)
MY (2) MY200364A (es)
SG (1) SG11202001637PA (es)
WO (1) WO2019060653A1 (es)
ZA (1) ZA202001167B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684793A1 (en) * 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022119076A1 (ko) * 2020-12-03 2022-06-09 이뮤노포지 주식회사 Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
CN119497630A (zh) * 2022-05-04 2025-02-21 免疫新炉有限公司 包含glp-1、免疫球蛋白fc和igf-1的融合蛋白及其用途
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011043530A1 (ko) * 2009-10-09 2011-04-14 (주)알테오젠 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
ES2617281T3 (es) 2009-10-28 2017-06-16 Janssen Biotech, Inc. Anticuerpos anti-glp-1r y sus usos
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
JP2015533483A (ja) 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
AU2014207748B2 (en) 2013-01-17 2018-10-11 Vtv Therapeutics Llc Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104098702B (zh) * 2014-07-23 2017-06-16 湖北工业大学 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用
CN106397606B (zh) * 2015-01-28 2020-11-10 中国科学院天津工业生物技术研究所 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物
PT3257524T (pt) 2015-02-11 2020-11-27 Gmax Biopharm Llc Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MX2018014966A (es) * 2016-06-09 2019-08-14 Medimmune Ltd Peptidos monolipidados resistentes a proteasas.
EP3684793A1 (en) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof

Also Published As

Publication number Publication date
SG11202001637PA (en) 2020-03-30
EP3684793A1 (en) 2020-07-29
US20210283225A1 (en) 2021-09-16
US12090193B2 (en) 2024-09-17
US20190091296A1 (en) 2019-03-28
CN111108117B (zh) 2024-08-06
IL304574B1 (en) 2025-04-01
JP2024178255A (ja) 2024-12-24
CN111108117A (zh) 2020-05-05
JP7789871B2 (ja) 2025-12-22
JP7559112B2 (ja) 2024-10-01
CA3073964A1 (en) 2019-03-28
AU2023223010A1 (en) 2023-11-09
AU2018338178A1 (en) 2020-04-02
AU2023223010B2 (en) 2025-12-04
KR20200054303A (ko) 2020-05-19
JP7239566B2 (ja) 2023-03-14
IL304574A (en) 2023-09-01
US11779633B2 (en) 2023-10-10
IL304574B2 (en) 2025-08-01
MY200364A (en) 2023-12-21
IL273253B1 (en) 2024-03-01
MY207828A (en) 2025-03-21
KR102696518B1 (ko) 2024-08-21
IL273253A (en) 2020-04-30
CN118955732A (zh) 2024-11-15
EA202090649A1 (ru) 2020-06-29
IL273253B2 (en) 2024-07-01
JP2020534016A (ja) 2020-11-26
WO2019060653A1 (en) 2019-03-28
ZA202001167B (en) 2024-06-26
US20240024428A1 (en) 2024-01-25
JP2023071827A (ja) 2023-05-23
US11045522B2 (en) 2021-06-29
AU2018338178B2 (en) 2023-06-08
US20250000949A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CL2020002477A1 (es) Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso
EA201792307A1 (ru) Способы репарации и регенерации тканей
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
DOP2017000258A (es) Proteínas de fusión
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX382848B (es) Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
MX382321B (es) Nuevo polipéptido con afinidad por pd-l1.
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
PE20260442A1 (es) Composiciones y metodos para tratar la enfermedad celiaca
MX375058B (es) Composiciones para usarse en tratar y prevenir la degeneración macular asociada a la edad.
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
MX2019012506A (es) Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.
MX2018003445A (es) Expresion de proteinas que contienen fc.